87 search results for SMAD3
| # | SuperPathway Name | Genes Count | Relevance Score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 51 | 2.251 | |||||||
|
||||||||||
| 2 | GDNF signaling | 132 | 0.392 | |||||||
|
||||||||||
| 3 | Gene expression (Transcription) | 1546 | 0.392 | |||||||
|
||||||||||
| 4 | NRP1-triggered signaling pathways in pancreatic cancer | 53 | 0.392 | |||||||
|
||||||||||
| 5 | Development_TGF-beta receptor signaling | 72 | 0.392 | |||||||
|
||||||||||
| 6 | Signal transduction_PKA signaling | 87 | 0.392 | |||||||
|
||||||||||
| 7 | Hypothesized pathways in pathogenesis of cardiovascular disease | 25 | 0.392 | |||||||
|
||||||||||
| 8 | TGF-beta receptor signaling | 50 | 0.392 | |||||||
|
||||||||||
| 9 | Interleukin-37 signaling | 21 | 0.392 | |||||||
|
||||||||||
| 10 | Endoderm differentiation | 71 | 0.392 | |||||||
|
||||||||||
| 11 | CCL18 signaling pathway | 96 | 0.392 | |||||||
|
||||||||||
| 12 | Mesodermal commitment pathway | 146 | 0.392 | |||||||
|
||||||||||
| 13 | PAK Pathway | 686 | 0.392 | |||||||
|
||||||||||
| 14 | TGF-beta Signaling Pathways | 96 | 0.392 | |||||||
|
||||||||||
| 15 | Ovarian infertility | 36 | 0.392 | |||||||
|
||||||||||
| 16 | Transcription_Role of VDR in regulation of genes involved in osteoporosis | 45 | 0.392 | |||||||
|
||||||||||
| 17 | Signaling by TGFB family members | 122 | 0.392 | |||||||
|
||||||||||
| 18 | Extracellular vesicle-mediated signaling in recipient cells | 28 | 0.392 | |||||||
|
||||||||||
| 19 | MIF Mediated Glucocorticoid Regulation | 681 | 0.392 | |||||||
|
||||||||||
| 20 | Endometrial cancer | 201 | 0.392 | |||||||
|
||||||||||
| 21 | Interleukin-1 family signaling | 153 | 0.392 | |||||||
|
||||||||||
| 22 | CCR5 Pathway in Macrophages | 321 | 0.392 | |||||||
|
||||||||||
| 23 | Th17 Differentiation | 62 | 0.392 | |||||||
|
||||||||||
| 24 | ERK Signaling | 1185 | 0.392 | |||||||
|
||||||||||
| 25 | Deubiquitination | 298 | 0.392 | |||||||
|
||||||||||
| 26 | Notch Signaling Pathways | 100 | 0.392 | |||||||
|
||||||||||
| 27 | DNA damage response (only ATM dependent) | 101 | 0.392 | |||||||
|
||||||||||
| 28 | Regulation of cytoplasmic and nuclear SMAD2/3 signaling | 13 | 0.392 | |||||||
|
||||||||||
| 29 | Adipogenesis | 131 | 0.392 | |||||||
|
||||||||||
| 30 | SMAD2/3 MH2 Domain Mutants in Cancer | 3 | 0.392 | |||||||
|
||||||||||
| 31 | Immune response IL-2 activation and signaling pathway | 75 | 0.392 | |||||||
|
||||||||||
| 32 | VEGF Signaling Pathway | 93 | 0.392 | |||||||
|
||||||||||
| 33 | Neovascularisation processes | 34 | 0.392 | |||||||
|
||||||||||
| 34 | TGF-beta receptor signaling in skeletal dysplasias | 59 | 0.392 | |||||||
|
||||||||||
| 35 | Neuroinflammation and glutamatergic signaling | 140 | 0.392 | |||||||
|
||||||||||
| 36 | Development_Glucocorticoid receptor signaling | 41 | 0.392 | |||||||
|
||||||||||
| 37 | TGF-Beta Pathway | 653 | 0.392 | |||||||
|
||||||||||
| 38 | GPCR Pathway | 712 | 0.392 | |||||||
|
||||||||||
| 39 | TGF-beta receptor signaling activates SMADs | 46 | 0.392 | |||||||
|
||||||||||
| 40 | CKAP4 signaling pathway map | 108 | 0.392 | |||||||
|
||||||||||
| 41 | Packaging Of Telomere Ends | 203 | 0.392 | |||||||
|
||||||||||
| 42 | TGFBR1 KD Mutants in Cancer | 10 | 0.392 | |||||||
|
||||||||||
| 43 | FOXO-mediated transcription | 65 | 0.392 | |||||||
|
||||||||||
| 44 | Metabolism of proteins | 1970 | 0.392 | |||||||
|
||||||||||
| 45 | Cell cycle | 137 | 0.392 | |||||||
|
||||||||||
| 46 | TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition | 14 | 0.392 | |||||||
|
||||||||||
| 47 | Epithelial to mesenchymal transition in colorectal cancer | 161 | 0.392 | |||||||
|
||||||||||
| 48 | SARS-CoV-1-host interactions | 142 | 0.392 | |||||||
|
||||||||||
| 49 | SMAD Signaling Network | 121 | 0.392 | |||||||
|
||||||||||
| 50 | Progeria-associated lipodystrophy | 19 | 0.392 | |||||||
|
||||||||||
| 51 | Angiotensin II receptor type 1 pathway | 28 | 0.392 | |||||||
|
||||||||||
| 52 | Cytokine Signaling in Immune system | 732 | 0.392 | |||||||
|
||||||||||
| 53 | Overlap between signal transduction pathways contributing to LMNA laminopathies | 62 | 0.392 | |||||||
|
||||||||||
| 54 | Bacterial infections in CF airways | 97 | 0.392 | |||||||
|
||||||||||
| 55 | Pre-NOTCH Expression and Processing | 235 | 0.392 | |||||||
|
||||||||||
| 56 | Vitamin D in inflammatory diseases | 9 | 0.392 | |||||||
|
||||||||||
| 57 | IL-2 Gene Expression in Activated and Quiescent T-Cells | 35 | 0.392 | |||||||
|
||||||||||
| 58 | Nervous system development | 1168 | 0.392 | |||||||
|
||||||||||
| 59 | Regulation of Telomerase | 68 | 0.392 | |||||||
|
||||||||||
| 60 | Canonical and non-canonical TGF-B signaling | 17 | 0.392 | |||||||
|
||||||||||
| 61 | Wnt / Hedgehog / Notch | 182 | 0.392 | |||||||
|
||||||||||
| 62 | HIF-1-alpha transcription factor network | 65 | 0.392 | |||||||
|
||||||||||
| 63 | Urotensin-II-mediated signaling pathway | 45 | 0.392 | |||||||
|
||||||||||
| 64 | Envelope proteins and their potential roles in EDMD physiopathology | 36 | 0.392 | |||||||
|
||||||||||
| 65 | Burn wound healing | 75 | 0.392 | |||||||
|
||||||||||
| 66 | Validated targets of C-MYC transcriptional activation | 80 | 0.392 | |||||||
|
||||||||||
| 67 | Senescence and autophagy in cancer | 105 | 0.392 | |||||||
|
||||||||||
| 68 | Signal Transduction | 2590 | 0.392 | |||||||
|
||||||||||
| 69 | Regulation of nuclear SMAD2/3 signaling | 74 | 0.392 | |||||||
|
||||||||||
| 70 | Signaling by NODAL | 22 | 0.392 | |||||||
|
||||||||||
| 71 | Regulation of activated PAK-2p34 by proteasome mediated degradation | 978 | 0.392 | |||||||
|
||||||||||
| 72 | SARS-CoV-2 innate immunity evasion and cell-specific immune response | 50 | 0.392 | |||||||
|
||||||||||
| 73 | RAF/MAP kinase cascade | 571 | 0.392 | |||||||
|
||||||||||
| 74 | Toll-like receptor signaling pathway | 285 | 0.392 | |||||||
|
||||||||||
| 75 | SARS-CoV-2 Infection | 414 | 0.392 | |||||||
|
||||||||||
| 76 | Activation of cAMP-Dependent PKA | 632 | 0.392 | |||||||
|
||||||||||
| 77 | Infectious disease | 1747 | 0.392 | |||||||
|
||||||||||
| 78 | Innate Immune System | 2025 | 0.392 | |||||||
|
||||||||||
| 79 | Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling | 36 | 0.392 | |||||||
|
||||||||||
| 80 | Androgen receptor network in prostate cancer | 105 | 0.392 | |||||||
|
||||||||||
| 81 | Human Embryonic Stem Cell Pluripotency | 186 | 0.392 | |||||||
|
||||||||||
| 82 | Colorectal Cancer Metastasis | 165 | 0.392 | |||||||
|
||||||||||
| 83 | Hepatitis C and hepatocellular carcinoma | 55 | 0.392 | |||||||
|
||||||||||
| 84 | Transcription Androgen Receptor nuclear signaling | 98 | 0.392 | |||||||
|
||||||||||
| 85 | Cell cycle Regulation of G1/S transition (part 1) | 124 | 0.392 | |||||||
|
||||||||||
| 86 | Beta-2 adrenergic-dependent CFTR expression | 167 | 0.392 | |||||||
|
||||||||||
| 87 | Cytokine production by Th17 cells in CF (Mouse model) | 54 | 0.392 | |||||||
|
||||||||||